|
Press Releases |
|
|
|
Wednesday, July 8, 2020 |
|
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong |
Eisai Co., Ltd. announced today that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance, has been accepted by the Hong Kong Department of Health. more info >> |
|
エーザイ、抗がん剤タゼメトスタットについて日本においてEZH2遺伝子変異陽性の濾胞性リンパ腫に係る適応で新薬承認申請書を提出 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、日本において、EZH2阻害剤タゼメトスタット臭化水素酸塩(一般名、以下 タゼメトスタット)について、EZH2 遺伝子変異陽性の濾胞性リンパ腫に係る適応で新薬承認申請書を提出したことをお知らせします。 more info >> |
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma |
Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for the EZH2 inhibitor tazemetostat hydrobromide (generic name, development code: E7438, "tazemetostat") for EZH2 gene mutation-positive follicular lymphoma. more info >> |
|
Monday, July 6, 2020 |
|
エーザイ、抗てんかん剤「フィコンパ(R)」(一般名:ペランパネル水和物)の新剤形となる細粒剤を新発売 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、日本において、自社創製の抗てんかん剤「フィコンパ(R)」(一般名:ペランパネル水和物、海外製品名:「Fycompa(R)」)の新しい剤形となる細粒剤を、本日、新発売したことをお知らせします。本剤形は、2020 年 1 月 23 日に製造販売承認され、4 月 23 日に薬価収載されました。 more info >> |
|
エーザイ、自社創製の新規不眠症治療薬「デエビゴ(R)」(一般名:レンボレキサント)が日本において不眠症に対する適応で新発売 |
エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、本日、不眠症を効能・効果とする、自社創製のオレキシン受容体拮抗薬「デエビゴ(R)錠 2.5mg、同錠 5mg および同錠 10mg」(一般名:レンボレキサント)を、日本において、新発売したことをお知らせいたします。本製品は、2020 年 1 月 23日に製造販売承認を取得し、4 月 22 日に薬価収載されました。 more info >> |
|
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan |
Eisai Co., Ltd. announced today that it has launched its in-house-discovered and developed orexin receptor antagonist DAYVIGO 2.5 mg, 5 mg, 10 mg tablets (lemborexant) for treatment of insomnia in Japan on July 6, 2020. more info >> |
|
Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan |
Eisai Co., Ltd. announced today that it has launched a new fine granule formulation of its in-house-discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) in Japan on July 6, 2020. more info >> |
|
Wednesday, July 1, 2020 |
|
Remap-Cap to Partner With Eisai on Innovative Trial to Combat COVID |
The Global Coalition for Adaptive Research (GCAR), in collaboration with UPMC (University of Pittsburgh Medical Center), and Eisai announced today that Eisai will join REMAP-COVID, a substudy of REMAP-CAP (A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia) that tests multiple interventions for the treatment of patients hospitalized with COVID-19. more info >> |
|
GCARとエーザイ、中等度から重度のCOVID-19感染患者様に対する治療薬創出を目指す革新的アダプティブデザインによる臨床試験(REMAP-COVID)を開始 |
Global Coalition for Adaptive Researchは、このたび、University of Pittsburgh Medical Centerと共同でCOVID-19による入院患者様に対する複数の治療薬の効果を確認する革新的なアダプティブプラットフォーム臨床試験*であるREMAP-CAP(A Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia)のサブスタディーとなるREMAP-COVIDを実施することをお知らせします。 more info >> |
|
Thursday, June 25, 2020 |
|
Eisai Receives Approval for Parkinson's Disease Treatment Equfina in South Korea |
Eisai Co., Ltd. announced today that Eisai Korea Inc., Eisai's subsidiary in South Korea, has received marketing approval of Parkinson's disease treatment Equfina (safinamide mesilate, "safinamide"). more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
JuicyBet Launches Its Innovative GambleFi Platform
May 2, 2024 11:00: JST
|
|
|
Hong Kong International Licensing Show creates cross-industry business opportunities
May 2, 2024 10:30 HKT/SGT
|
|
|
Ordify Employs Blockpass to Open Investment to Everyone
May 2, 2024 10:00 HKT/SGT
|
|
|
JuicyBet Launches Its Innovative GambleFi Platform
May 2, 2024 10:00 HKT/SGT
|
|
|
Q&M Dental Enhances Digital Capabilities by Integrating Align Technology's Newest iTero Lumina(TM) Intraoral Scanner Across Dental Clinics in Singapore
May 2, 2024 11:00 JST
|
|
|
Loop Industries and Ester Industries Ltd. Announce Joint Venture Agreement to Build an Infinite Loop(TM) Manufacturing Facility in India
May 2, 2024 09:30 HKT/SGT
|
|
|
Paltalk to Host First Quarter 2024 Earnings Results Conference Call on Thursday, May 9, 2024 at 9:00 a.m. ET
May 2, 2024 00:28 HKT/SGT
|
|
|
PodcastOne (Nasdaq: PODC) Acquires Exclusive Sales and Distribution Rights to Dumb Gay Podcast
May 2, 2024 00:19 HKT/SGT
|
|
|
Forian Inc. to Announce First Quarter 2024 Results on May 14, 2024
May 2, 2024 00:09 HKT/SGT
|
|
|
Vietnam to Rethink Financial Services After a Cutting-edge Show at WFIS
May 1, 2024 15:42 HKT/SGT
|
|
|
国美金融科技发布2023年度报告 商业保理稳中向好 多元化协同发展
May 1, 2024 13:18 HKT/SGT
|
|
|
國美金融科技發佈2023年度報告 商業保理穩中向好 多元化協同發展
May 1, 2024 13:12 HKT/SGT
|
|
|
Anson Resources Signs Lithium Supply Agreement with LG Energy Solution
May 1, 2024 09:00 HKT/SGT
|
|
|
The 16th Annual Global CSR & ESG Summit and Awards 2024: Celebrating Sustainable Leadership and Innovation, 25 April 2024
Apr 30, 2024 19:40 HKT/SGT
|
|
|
Q2 Metals Announces Completion of Drill-Core Re-Evaluation for the Cisco Lithium Property, James Bay Territory, Quebec, Canada
Apr 30, 2024 19:09 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|